Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

Filter conferences

 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
      
      
 
      
 
      
      
      
      
      
      
      
      
      
      
5th IPF Summit | Virtual Event | August 25-27

5th IPF Summit | Virtual Event | August 25-27

Categories

Date of beginning

Wednesday, 25 August 2021

Duration

3 days

City

Virtual

Contact

Caroline Hunt

E-Mail

This email address is being protected from spambots. You need JavaScript enabled to view it.

Memo

From Dissecting Mechanisms of Epithelial Dysfunction to Discovering Patient Reported Outcomes for More Meaningful Clinical Trials, Uncover Scientific Advancements and Actionable Insights to Optimize IPF Drug Development Returning with a revitalized agenda including 25 brand new speakers, the hotly anticipated two-tracked summit is back! As epithelial targets return to the limelight, innovations in translational models hit their stride and clinical trial competition dramatically heats up; there’s more translational and clinically relevant science for IPF now than ever before, catapulting this archetypal fibrotic disease right to the top of biopharma’s priority list. Dedicated to providing you with the insights you need to create clinically defining IPF therapeutics, this premier industry forum will unite industry experts from AstraZeneca, Genentech, Ionis, AbbVie, Gilead, Lassen Therapeutics, Pliant, Galecto and more with leading academia, for you to gain back-to-back insights on the science propelling IPF drug development forward. From dissecting the fibrotic lung microenvironment and comprehensively analyzing multiple translational models alongside bleomycin to including patient-reported outcomes as an endpoint in clinical trials; the 5th IPF Summit is the only end-to-end forum presenting scientific advancements as actionable insights for more innovative and clinically effective drug development. As organizations across fibrosis, autoimmunity and inflammatory disease turn their heads towards IPF in a bid to capitalize on its strategic opportunity, Join 150+ IPF drug developers this August at this unique forum for a dynamic mix of formal presentations, audience discussions, panel discussions and organized networking and leave with the expertise your team needs to optimize your IPF R&D for 2021 and beyond. Want to learn more about our brand new 2021 agenda and expert speaker faculty? Visit: https://ter.li/fg78l4 Date and Time: On Wednesday August 25, 2021 at 9:00 am (ends Friday August 27, 2021 at 5:00 pm) Prices: Industry Pricing - FULL ACCESS: Conference + 2 Workshops (EBs available): USD 2797.00,Industry Pricing - Conference Only (EBs available): USD 2099.00,Academic Pricing - FULL ACCESS: Conference + 2 Workshops (EBs available): USD 2497.00,Academic Pricing - Conference Only (EBs available): USD 1899.00 URL: Tickets: https://go.evvnt.com/781993-1?pid=5569 Speakers: Andrei Gudkov Chief Science Officer Genome Protection, Andrew Thorley Fibrosis Therapeutic Area Lead - OMNI Biomarker Development Genentech, Anjaly Pandey Senior Vice President of Nonclinical and Chemistry twoXAR Pharmaceuticals, Bethany Moore Chair - Microbiology and Immunology University of Michigan, Cory Hoagaboam Chief Scientific Officer Lung Therapeutics, Courtney Schiffman Senior Statistical Scientist Genentech, Derek Mann Dean of Research and Innovation Newcastle University, Fernando Martinez Chief Division of Pulmonary and Critical Care Medicine Cornell University, Gary Matthew Hunninghake Associate Professor of Medicine Harvard Medical School, Greg Cosgrove Vice President Clinical Development Pliant Therapeutics, Hartmut Beck Bayer Science Fellow and Laboratory Head of Medicinal Chemistry Bayer Pharmaceuticals, Imre Noth Professor of Medicine University of Virginia School of Medicine, James Swaney Vice President - Fibrosis and Translational Biology Lassen Therapeutics, Jane Connor Associate Director AstraZeneca, Jeff Crosby Director of Pulmonary Drug Discovery Ionis Pharmaceuticals, Kristoffer Ostridge Physician Director AstraZeneca, Lee Borthwick Professor University of Newcastle, Lewis Gruber Chief Scientific Officer Siwa Therapeutics, Jeff Swigris Professor National Jewish, Jesse Roman Ludwig Kind Professor of Medicine and Pharmacology Thomas Jefferson University, Kjetil Ask Associate Professor of Medicine McMaster University, Lisa Hazelwood Principal Research Scientist Immunology and Fibrosis AbbVie, Martin Kolb Director - Division of Respirology McMaster University, Mary Salvatore Associate Professor Thoracic Radiology Columbia University Medical Center, Min Lu Senior Director and Head of Fibrosis Morphic Therapeutics, Naftali Kaminski Professor of Internal Medicine Yale University School of Medicine, Philip Molyeanux Clinical Senior Lecturer in Interstitial Lung Disease Imperial College London, Rachel Knipe Instructor in Medicine Massachusetts General Hospital, Rob Slack Vice President and Head of Pharmacology Galecto, Ruchi Gupta Senior Associate Director Gilead Sciences, Samir Ounzain Co-Founder and Chief Executive Officer HAYA Therapeutics, Steven Engle Chief Executive Officer CohBar, Timothy Blackwell Professor Vanderbilt University, Toby Maher Director Interstitial Lung Disease Program USC, Tushar Desai Assistant Professor Stanford University Medical Center, Ulf Hedstrom Senior Research Scientist AstraZeneca